Entropy Technologies LP Purchases Shares of 29,711 Pfizer Inc. (NYSE:PFE)

Entropy Technologies LP acquired a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 29,711 shares of the biopharmaceutical company's stock, valued at approximately $860,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Olistico Wealth LLC bought a new stake in Pfizer during the second quarter worth about $25,000. MFA Wealth Advisors LLC bought a new stake in shares of Pfizer during the 2nd quarter worth approximately $29,000. Quarry LP bought a new stake in shares of Pfizer during the 2nd quarter worth approximately $31,000. Financial Connections Group Inc. acquired a new stake in shares of Pfizer during the 2nd quarter worth approximately $34,000. Finally, ESL Trust Services LLC acquired a new position in Pfizer during the first quarter valued at approximately $37,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Barclays raised their target price on Pfizer from $30.00 to $32.00 and gave the company an "equal weight" rating in a report on Wednesday, July 31st. Cantor Fitzgerald reiterated an "overweight" rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Evercore ISI raised Pfizer to a "strong-buy" rating in a research note on Wednesday, October 30th. UBS Group raised their price target on shares of Pfizer from $30.00 to $31.00 and gave the company a "neutral" rating in a research note on Wednesday, July 31st. Finally, StockNews.com upgraded shares of Pfizer from a "buy" rating to a "strong-buy" rating in a research report on Tuesday. Eight research analysts have rated the stock with a hold rating, five have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $33.58.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Trading Down 0.6 %

NYSE:PFE traded down $0.17 during trading hours on Thursday, hitting $26.55. 13,759,264 shares of the company were exchanged, compared to its average volume of 37,668,590. The company has a fifty day simple moving average of $28.76 and a 200 day simple moving average of $28.67. Pfizer Inc. has a one year low of $25.20 and a one year high of $31.54. The stock has a market capitalization of $150.46 billion, a price-to-earnings ratio of 35.74, a price-to-earnings-growth ratio of 0.83 and a beta of 0.67. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts' consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same period in the previous year, the firm earned ($0.17) earnings per share. The firm's quarterly revenue was up 31.2% on a year-over-year basis. Sell-side analysts expect that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.33%. The ex-dividend date is Friday, November 8th. Pfizer's dividend payout ratio is currently 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.